Product information and disease descriptionPlace of product in therapyDisease description
Natural history, survival, and mortality
13 evidence topics · 10 sources
Insulinoma: survival by indolent or aggressive behavior across published series
“Approximately 10% to 15% of insulinomas belong to the aggressive category and 85% to 90% can be considered as indolent” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with an aggressive insulinoma have lower survival compared with patients with an indolent insulinoma.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The 5-year survival of patients with an indolent insulinoma has been reported to be 94% to 100% and for patients with an aggressive insulinoma this amounts to 24% to 67%” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Insulinoma: survival of non-metastatic and metastatic disease in a nationwide Finnish cohort
“Overall survival was analysed with Kaplan–Meier and Cox regression analyses.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“During the follow-up, 25 (32%) patients and 63 (20%) controls deceased.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In a Cox regression analysis, the median overall survival of 27.5 (95% CI: 24.1–30.8) years in the patients with a non-metastatic insulinoma did not significantly differ from the 33.2 (29.8–36.7) years in their controls (HR: 1.5 (0.9–2.6), P = 0.128).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the patients with a metastatic insulinoma, the survival was significantly impaired, with a median of 3.4 (2.9–4.0) years vs not reached in the controls (HR: 5.1 (1.9–13.3), P = 0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Three of the patients with metastatic insulinoma (33%), however, showed a remarkably long survival time of 6–30 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the multivariate analyses, older age and distant metastases were associated with decreased survival” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Insulinoma: causes of death and perioperative mortality in a nationwide Finnish cohort
“Nine of the 25 insulinoma patients who deceased during the study period (36%) died due to an insulinoma-related cause: 6 patients died of metastatic insulinoma, 2 patients died of surgical complications, and 1 patient died due to complications of invasive diagnostics, as previously described” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“With the two deaths due to surgical complications, the perioperative mortality, defined as any death occurring within 30 days after surgery, was 2.7%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Insulinoma: recurrence after curative-intent surgery
Insulinoma: long-term survival of a 60-year Mayo Clinic cohort
“we found 224 patients in whom an initial pancreatic exploration at Mayo had confirmed the presence of insulinoma.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“For the total cohort, 7.6% had multiple endocrine neoplasia type I (MEN I), and 5.8% had malignant insulinoma.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Although survival of the total cohort was not significantly impaired, it was significantly worse than expected for patients with malignant insulinoma (29% versus 88% expected at 10 years postoperatively).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Insulinoma: survival of benign versus malignant disease at a single institution
“A total of 311 patients were identified: 51 malignant and 260 benign.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Overall survival at 5 years was 66.8% vs 95.4% for malignant and benign insulinoma respectively, p < 0.01.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Malignant insulinoma: population-based survival in the SEER registries
“A total of 121 cases of malignant insulinoma were identified between 1973 and 2015.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The median overall survival (OS) was 143 months, with 5-and 10-year OS observed in 58% and 55%, respectively” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“5-year OS was 84% and 14% for the surgery and no-surgery groups, respectively, p < 0.001.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“On multivariable analysis, surgical resection, male sex, and absence of metastatic disease were associated with greater overall and cancer-specific survival” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Malignant insulinoma: survival and prognostic factors in an Italian multicenter series
“Multicenter retrospective study on 31 patients (male: 61.3%) diagnosed between 1988 and 2017.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The 5-year survival rate was 62%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Overall survival was significantly higher in patients with Ki-67 ≤10% (P = 0.03), insulin level <60 µU/mL (P = 0.015) and in patients who underwent surgery (P = 0.006).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Malignant insulinoma: onset of hypoglycemia after a non-functioning tumor
“In 16.1% of the cases, the hypoglycaemic syndrome occurred after 46 ± 35 months from the diagnosis of originally non-functioning NET, whereas in 83.9% of the cases it led to the diagnosis of NET, of which 42.3% with a mean diagnostic delay of 32.7 ± 39.8 months.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Metastatic insulinoma: variable natural history in a National Institutes of Health series
“The authors identified 10 patients with metastatic insulinoma.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Second, four patients presented with metastatic disease to the liver, which appeared years after the initial diagnosis and presumed curative surgery.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Finally, 9 of the 10 patients had a prolonged survival.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The current study, as well as others, suggested that metastatic insulinoma may have a variable natural history.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Metastatic insulinoma: survival with multimodal treatment at a tertiary center
“Clinical data on 14 patients with metastatic insulinoma (metastases to the liver, skeleton, and lung) were reviewed in this descriptive study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Seven subjects died during follow-up. The time of the 7 deaths ranged from 2.5 to 10.4 years (median time to death was 8.2 years).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This compares to previous reports of median survival of about 2 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Seven subjects are alive 1.2-12.3 years after diagnosis. Hypoglycemia was well-controlled and did not cause the deaths.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
NICTH: recovery and in-hospital mortality in a systematic review of published cases
“Outcome data included tumour recurrence, hypoglycaemia and in‐hospital mortality.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Outcomes were available for 223 cases, and the overall recovery rate among all the participants was 77% (n = 172).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Most patients successfully recovered (77%); however, a significant mortality rate was identified (23%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Chronic liver disease (CLD) was more likely to be associated with death than recovery (OR: 7.23, P: 0.03).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Fibrous tumours were significantly associated with recovery compared to non‐fibrous ones, and the association was statistically significant (65.1% vs. 33%, p < .001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote